BioStock: CombiGene advances preclinically and recruits post-doc
On Monday, CombiGene announced that all quality analyses of the gene therapy drug candidate CG01 have been successfully completed prior to the final steps of the preclinical program. To secure important competence for the clinical program with CG01, which is planned for next year, Esbjörn Melin has been recruited to the position as industrial post-doc. BioStock contacted CombiGene’s CEO Jan Nilsson for a comment.
Read the full interview with Jan Nilsson at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/